INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2013

Oral yeast-derived β-(1-3) glucan increased salivary lysozyme and CRP and improved general conditions in children with chronic respiratory problems.

A placebo-driven clinical trial evaluated the effects of a 100 mg/d oral dose of yeast-derived β-(1-3) glucan in 40 children aged 8-12 years with chronic respiratory problems. Researchers measured salivary levels of albumin, lysozyme, and CRP. Glucan treatment resulted in a significant increase in the production of lysozyme and CRP, along with a strong improvement in general conditions.

Study type
Placebo-driven clinical trial
Who was studied
40 children aged 8-12 years with chronic respiratory problems
What was measured
Salivary levels of albumin, lysozyme, and CRP; general conditions

THE PAPER

Placebo-driven clinical trials of yeast-derived β-(1-3) glucan in children with chronic respiratory problems.

Vetvicka V, Richter J, Svozil V, Rajnohová Dobiášová L, Král V. Ann Transl Med, 2013.

PubMed 25332970 ↗DOI 10.3978/j.issn.2305-5839.2013.07.01 ↗

Other health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.